Abstract The author reports herein the fourth case of rare clear cell adenocarcinoma (CCA) of ureter. The present case is the first of ureter CCA with extensive immunohistochemical examination. The patient is a 61-year-old man. The CCA was composed of malignant cells with very clear ample cytoplasm with occasional glandular formations. No apparent hobnail cells were seen. The tumor cells were seen to invade the adventitia. No carcinoma in situ was seen in the surrounding urothelium. A lymph showed metastasis. Histochemical stains revealed that the clear cytoplasm was due to glycogen not mucins or lipids.
Introduction
Most carcinoma of urinary system is urothelial carcinoma [1] . According to WHO, urothelial carcinoma of urinary system shows many histological variants. These variants includes squamous differentiation variant, glandular differentiation variant, nested variant [2] , microcystic variant, micropapillary variant, lymphoepithelioma-like variant, lymphoma-like variant, plasmacytoid variant, sarcomatoid variant [3] [4] [5] and so on. Signet-ring cell carcinoma and small cell carcinoma of urinary system have also been reported [6] [7] [8] [9] .
Clear cell adenocarcinoma (CCA) of urinary bladder (UB) is rare [10] . CCA of urinary tract is defined as a distinct variant of adenocarcinoma of urinary system that resembles its Mullerian counterpart in female genital tract. CCA of urinary system is the urinary counterpart of much more common CCA of female genital tract. Only several case series of CCA of genitourinary system have been reported in literature. The author reported an autopsy case of CCA of UB [10] . CCA is more frequent in urethra than in UB. CCA of UB most often affects female. CCA may resemble nephrogenic metaplasia. CCA of UB may show differentiation into nephrogenic metaplasia or Mullerian phenotypes. Extensive immunohistochemical study of CCA of UB has rarely been performed [10] .
CCA occurs exclusively in urethra and urinary bladder in the urinary system. CCA of ureter is extremely rare. There have been only 3 case reports of CCA of ureter in world literature. There are no immunohistochemical studies of CCA of ureter. Herein reported is a surgical case of CCA of ureter. An extensive immunohistochemical study was performed.
Case report
A 61-year-old man presented with three primary carcinomas (colonic adenocarcinoma, prostatic adenocarcinoma Gleason 8, ureter CCA) by various modalities; each of them was confirmed by pathological examinations in addition to various imaging and endoscopic techniques. The colonic adenocarcinoma was found at 57 years of age and treated by colectomy followed by chemotherapy; no recurrence was noted. The prostatic adenocarcinoma was found at 59 years of age, and treated by internal irradiation and hormone therapy. The present case of CCA of ureter was found at 61 years of age, and was manifested with bladder irradiation symptoms and hematuria. The TNM classification and NCI stage of colonic carcinoma were pT3N0M0 and stage 2A (Dukes B), those of prostatic adenocarcinoma were cT2N0M0 and stage 2B, and the ureter tumor were cT3N0M0 and over stage 3.
Macroscopical pathological examination showed a tumor of middle part of right ureter (Fig. 1) .
Microscopically, right ureter tumor was composed of characteristic malignant cells with very clear cytoplasm and hyperchromatic, atypical nuclei (Fig. 2 ). There were luminal formations in certain places (Fig. 2) . No apparent hobnail cells were seen. The tumor cells were seen in the all layers of the ureter, and were seen to invade the adventitia (more than pT3 of UICC). A lymph node of right common iliac area showed metastasis. No carcinoma in situ was seen.
Histochemistry was performed by several methods as previously reported [10] [11] [12] [13] [14] , and it revealed glycogens but not lipid or mucins. An immunohistochemical study was carried out with the use of Envision techniques and their variations as reported previously [15] [16] [17] [18] [19] [20] Immunohistochemical results are summarized in Table 1 . The tumor cells were positive for cytokeratin (CK) AE1/3, CK CAM5.2 (Fig. 3) , CK34BE12, CK8, CK18, EMA, CEA, CA19-9 (Fig. 4) , p53, PDGFRA, MUC-1, and Ki-67 (labeling index = 26%). Tumor cells were negative for CK5/6, CK7, CK14, CK19, CK20, neuron-specific enolase (NSE), p63, vimentin, S100 protein, α-smooth muscle actin (ASMA), c-erbB2, chromogranin, synaptophysin, KIT (CD117), CD56, CDX-2, MUC2, MUC5AC, and MUC6. The normal urothelium was positive for glycogen and negative for mucins. The normal epithelium was immunohistochemically positive for CK AE1/3, CK CAM5.2, CK34BE12, CK5/6, CK7, CK8, CK18, CK19, EMA, p63, CEA, MUC1, and Ki-67 antigen (labeling index = 5%). The normal urothelium was negative for CK14, CK20, CEA, vimentin, NSE, S100 protein, ASMA, CA19-9, c-erbB2, p53, chromogranin, synaptophysin, KIT, PDGFRA, CD56, MUC2, MUC5AC, and MUC6. The patient is now receiving chemotherapy and radiation therapies for ureter tumor and estrogen for prostatic carcinoma 7 months after the operation.
Discussion
CCA of urinary tract is defined as a distinct variant of adenocarcinoma of urinary system that resembles its Mullerian counterpart in female genital tract [12] . CCA of urinary system is basically urinary counterpart of much more common CCA of female genital tract. CCA of male and female genital tracts is characterized by adenocarcinoma with clear cells. The clear cytoplasm is due to glycogen. No mucins or lipid are present in cytoplasm. CCA is characterized also by hobnails cells. In the present ureter tumor, it was apparent that cytoplasm contained glycogen but not mucins or lipid. Mucins were seen only within lumens. The present ureter tumor occasionally showed glandular structures. The negative immunoreactive S100 protein, an antigen of fat cells, in the current ureter tumor suggests that the clear cytoplasm suggests no lipid deposition in the tumor. The positive CEA and CA19-9 suggest the glandular differentiation. Although no apparent hobnail cells were seen, the present case fulfills the criteria of CCA. The present CCA of ureter must be differentiated from several variants of urothelial carcinoma (UC), including clear cell variant, nested variant [2] , microcystic variant, and lipid-cell variant. The present tumor is basically an adenocarcinoma with gland formation (CCA). In nested variant of UC, the atypia is mild and there are no gland formations [1, 2] . The present ureter CCA is different from lipid-cell variant of UC, because the clearness of the cytoplasm was due not to lipid or mucins. CCA of urinary system must be differentiated from nephrogenic metaplasia and adenoma. The present primary CCA of the ureter is not nephrogenic metaplasia because this case showed cellular atypia regarded as malignancy.
Malignant tumors composed of clear malignant cells can occur in any organs; the most common is clear cell RCC. The present tumor is not clear cell RCC, because the present tumor was negative for CD1 and RCC markers and is negative for fat. Primary CCA of urinary system is very rare; only a small number of cases have been reported [10] . The majority occurs in female urinary bladder. In ureter, there have been only three case reports of primary CCA of ureter in world literature. Thus, the present case is extremely rare, and is the fourth case of primary CCA of ureter. The present case is the first of primary CCA of ureter with an immunohistochemical study.
Immunohistochemical studies of CCA of urinary system have rarely been done [10] . In the author's previous autopsy case of primary CCA of bladder [10] , no glycogens or mucins were recognized in tumor cells. Immunohistochemically, tumor cells of CCA of bladder of the author's previous autopsy case were positive for CK AE1/3, CK CAM5.2, CK34βE12, CK 7, CK 8, CK 18, CK19, EMA, CEA, CA19-9, CA125, CD10, MUC1, p53 and Ki-67 (labeling = 40%). They were negative for CK5/6, CK14, CK20, estrogen receptor, progesterone receptor, α-methylacyl-CoAracemase, p63, CDX2, MUC2, MUC5AC, MUC6, CD45, CD34, vimentin, neuron-specific enolase, S100 protein, desmin, HMB45, AFP, α-smooth muscle actin, MDM2, HER2/neu, synaptophysin, and CD56. Thus, immunoprofiles were similar between the two.
CK profile of bladder CCA has not been investigated. The present ureter CCA tended to express low and mediummolecular weight CK, but not high-molecular weight CK. CK7/CK20 pattern was CK7 −/CD20 −; this pattern is frequently seen in RCC, suggesting that the present case CCA mimics RCC CK pattern and histology. The pattern is CK7+/ CK20− in bladder carcinoma, while RCC CK7−/CK20−.
Positive CEA, CA19-9 and MUC imply adenocarcinomatous nature. Expression of p53 and high Ki-67 suggests malignant potentials. Absence of p63 suggests negative squamous cell or urothelial differentiations. CDX-2 was absent in both the previous bladder CCA and current ureter CCA, indicating that the tumor is not associated with colorectal carcinoma. In the present case, no carcinoma in situ (CIS) was seen around the urothelial CCA, suggesting no lineage of CIS-invasive CCA in the present tumor.
Finally, the immunoprofile of the present tumor and normal urothelium (Table 1) was very similar. In particular, high molecular weight CKs such as CK34BE12 and CK5/6, which are known to be expressed in urothelium and urothelial carcinoma, were seen in the CCA of the present study. The author thinks that the present CCA of the ureter has arisen from usual urothelial carcinoma or urothelium.
The author has no conflict of interest. This study was performed by the author's own money, sparing any kinds of external funds.
